1
|
Adams D, Cintas P, Solé G, Tard C, Labeyrie C, Echaniz-Laguna A, Cauquil C, Pereon Y, Magy L, Morales RJ, Antoine JC, Lagrange E, Petiot P, Mallaret M, Francou B, Guiochon-Mantel A, Coste A, Demarcq O, Geffroy C, Famelart V, Rudant J, Bartoli M, Donal E, Lairez O, Eicher JC, Kharoubi M, Oghina S, Trochu JN, Inamo J, Habib G, Roubille F, Hagège A, Morio F, Cariou E, Adda J, Slama MS, Charron P, Algalarrondo V, Damy T, Attarian S. Transthyretin amyloid polyneuropathy in France: A cross-sectional study with 413 patients and real-world tafamidis meglumine use (2009-2019). Rev Neurol (Paris) 2024:S0035-3787(24)00489-2. [PMID: 38643028 DOI: 10.1016/j.neurol.2024.02.393] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/16/2023] [Revised: 02/09/2024] [Accepted: 02/14/2024] [Indexed: 04/22/2024]
Abstract
OBJECTIVE We aimed to describe characteristics of patients with ATTR variant polyneuropathy (ATTRv-PN) and ATTRv-mixed and assess the real-world use and safety profile of tafamidis meglumine 20mg. METHODS Thirty-eight French hospitals were invited. Patient files were reviewed to identify clinical manifestations, diagnostic methods, and treatment compliance. RESULTS Four hundred and thirteen patients (296 ATTRv-PN, 117 ATTRv-mixed) were analyzed. Patients were predominantly male (68.0%) with a mean age of 57.2±17.2 years. Interval between first symptom(s) and diagnosis was 3.4±4.3 years. First symptoms included sensory complaints (85.9%), dysautonomia (38.5%), motor deficits (26.4%), carpal tunnel syndrome (31.5%), shortness of breath (13.3%), and unexplained weight loss (16.0%). Mini-invasive accessory salivary gland or punch skin and nerve biopsies were most common, with a performance of 78.8-100%. TTR genetic sequencing, performed in all patients, revealed 31 TTR variants. Tafamidis meglumine was initiated in 156/214 (72.9%) ATTRv-PN patients at an early disease stage. Median treatment duration was 6.00 years in ATTRv-PN and 3.42 years in ATTRv-mixed patients. Tafamidis was well tolerated, with 20 adverse events likely related to study drug among the 336 patients. CONCLUSION In France, ATTRv patients are usually identified early thanks to the national network and the help of diagnosis combining genetic testing and mini-invasive biopsies.
Collapse
Affiliation(s)
- D Adams
- Department of Neurology, French Reference Center for Familial Amyloid Polyneuropathy, AP-HP, CHU de Bicêtre, University Paris-Saclay, Inserm U 1195, 78, rue du Général Leclerc, 94270 Le Kremlin-Bicêtre, France.
| | - P Cintas
- Centre de référence neuromusculaire, CHU de Toulouse, Toulouse, France
| | - G Solé
- Referral Center for Neuromuscular Diseases, Pellegrin Hospital, Bordeaux, France
| | - C Tard
- Centre de référence des maladies neuromusculaires, CHU de Lille, Lille, France
| | - C Labeyrie
- Department of Neurology, French Reference Center for Familial Amyloid Polyneuropathy, AP-HP, CHU de Bicêtre, University Paris-Saclay, Inserm U 1195, 78, rue du Général Leclerc, 94270 Le Kremlin-Bicêtre, France
| | - A Echaniz-Laguna
- Department of Neurology, French Reference Center for Familial Amyloid Polyneuropathy, AP-HP, CHU de Bicêtre, University Paris-Saclay, Inserm U 1195, 78, rue du Général Leclerc, 94270 Le Kremlin-Bicêtre, France
| | - C Cauquil
- Department of Neurology, French Reference Center for Familial Amyloid Polyneuropathy, AP-HP, CHU de Bicêtre, University Paris-Saclay, Inserm U 1195, 78, rue du Général Leclerc, 94270 Le Kremlin-Bicêtre, France
| | - Y Pereon
- Centre de référence maladies neuromusculaire rares, CHU Nantes, Nantes, France
| | - L Magy
- Centre de référence neuropathies périphériques rares, CHU de Limoges, Limoges, France
| | - R Juntas Morales
- Neurology Department, ALS center, University Hospital of Montpellier, Montpellier, France
| | - J C Antoine
- Centre de référence maladies neuromusculaires rares, CHU de Saint-Étienne, Saint-Étienne, France
| | - E Lagrange
- Neurology Department, CHU Michallon, Grenoble, France
| | - P Petiot
- Medicine, 64, avenue Rockefeller, Lyon, France
| | - M Mallaret
- Neurology Department, CHU Michallon, Grenoble, France
| | - B Francou
- Molecular Genetics Pharmacogenomics and Hormonology Department, hôpital Bicêtre, Le Kremlin-Bicêtre, France
| | - A Guiochon-Mantel
- Molecular Genetics Pharmacogenomics and Hormonology Department, hôpital Bicêtre, Le Kremlin-Bicêtre, France
| | - A Coste
- Pfizer, Paris cedex 14, France
| | | | | | | | | | | | - E Donal
- University of Rennes, CHU de Rennes, Rennes, France
| | - O Lairez
- Cardiology Department, Rangueil Hospital, Toulouse, France
| | - J C Eicher
- Cardiology Department, University Hospital of Dijon, Dijon, France
| | - M Kharoubi
- Referral Center for Cardiac Amyloidosis, CHU Henri-Mondor, Créteil, France
| | - S Oghina
- Referral Center for Cardiac Amyloidosis, CHU Henri-Mondor, Créteil, France
| | - J N Trochu
- Institut du thorax, CHU de Nantes, Nantes, France
| | - J Inamo
- Cardiology Department, CHU de Martinique, Martinique, France
| | - G Habib
- Cardiology Department, La Timone Hospital, AP-HM, Marseille, France
| | - F Roubille
- Cardiology Department, CHU de Montpellier, Montpellier, France
| | - A Hagège
- Cardiology Department, hôpital européen Georges-Pompidou, Paris, France
| | - F Morio
- Institut du thorax, CHU de Nantes, Nantes, France
| | - E Cariou
- Cardiology Department, Rangueil Hospital, Toulouse, France
| | - J Adda
- Cardiology Department, hôpital Bichat, Paris, France
| | - M S Slama
- Cardiology Department, hôpital Bichat, Paris, France
| | - P Charron
- Hôpital Pitié-Salpêtrière, Sorbonne université, Paris, France
| | | | - T Damy
- Referral Center for Cardiac Amyloidosis, CHU Henri-Mondor, Créteil, France
| | - S Attarian
- Neurology Department, La Timone Hospital, AP-HM, Marseille, France
| |
Collapse
|
2
|
Perrin A, Morales RJ, Chapon F, Thèze C, Lacourt D, Pégeot P, Uro-Coste E, Giovannini D, Leboucq N, Mallaret M, Rigau V, Gaudon K, Richard P, Koenig M, Métay C, Cossée M. OTHER NMDs. Neuromuscul Disord 2021. [DOI: 10.1016/j.nmd.2021.07.384] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
3
|
Duwez M, Szymanski G, Carre M, Mallaret M, Lepelley M. [Idiosyncratic drug-induced agranulocytosis: 7 year-analysis in a French university hospital]. Ann Pharm Fr 2020; 78:230-241. [PMID: 32248952 DOI: 10.1016/j.pharma.2020.02.004] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/11/2019] [Revised: 01/31/2020] [Accepted: 02/03/2020] [Indexed: 01/13/2023]
Abstract
INTRODUCTION Idiosyncratic drug-induced agranulocytosis is a rare but potentially serious haematological disorder. The pathophysiological mechanisms are complex and poorly understood. We aimed at investigating agranulocytosis drug related causes from the myelograms with "myeloid maturation arrest" performed in our university hospital over the last seven years. METHODS A retrospective analysis of myelograms collected for agranulocytosis was performed from 1st January 2010 to 31th December 2016. We used the method of Bégaud et al. for drug causality assessment. RESULTS Among the 104 myelograms analysed, 41 agranulocytosis were drug-induced, whose 28 were idiosyncratic. Among these 28 cases, 26 different drugs were involved. Agranulocytosis was a known adverse reaction in the summary of the product characteristics for 24 drugs, mainly associated with undetermined frequency (n=7). Mean onset latency was 38.1 days after starting the drug (calculated for n=23 cases) and granulocyte growth factors were used in 50% of cases without shortening the mean delay of blood count recovery. Bone marrow presented hypereosinophilia in 29% of cases. Pharmacovigilance reporting rate was 48%. CONCLUSION A "maturation arrest" in the myelogram is not pathognomonic for idiosyncratic drug-induced agranulocytosis. This rare event require multidisciplinary care involving haematologists, biologists and pharmacovigilance experts. Agranulocytosis reporting rate was high compared with usual adverse drug reaction reporting rate (5 to 10%), probably related to the potential severity of this event.
Collapse
Affiliation(s)
- M Duwez
- Département de pharmacie, CHU de Grenoble-Alpes, 38000 Grenoble, France.
| | - G Szymanski
- Laboratoire d'hématologie, CHU de Grenoble-Alpes, 38000 Grenoble, France
| | - M Carre
- Clinique universitaire d'hématologie, CHU de Grenoble-Alpes, 38000 Grenoble, France
| | - M Mallaret
- Centre régional de pharmacovigilance, CHU de Grenoble-Alpes, 38000 Grenoble, France
| | - M Lepelley
- Centre régional de pharmacovigilance, CHU de Grenoble-Alpes, 38000 Grenoble, France
| |
Collapse
|
4
|
Mallaret M, Micallef J. Cannabidiol et cannabinoïdes : nécessité d’une évaluation pharmacologique approfondie à des fins d’expertise clinique et réglementaire. Toxicologie Analytique et Clinique 2019. [DOI: 10.1016/j.toxac.2019.03.065] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
5
|
Frauger E, Spadari M, Pochard L, Fouilhé Sam-Laï N, Jouanjus E, Mallaret M, Micallef J. Quels sont les principaux faits marquants des 9 ans de suivi d’addictovigilance de la méthadone ? Toxicologie Analytique et Clinique 2018. [DOI: 10.1016/j.toxac.2018.04.017] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
6
|
Fouilhé Sam-Laï N, Eysseric H, Yahiaoui N, Gaulier JM, Dumestre-Toulet V, Mallaret M. Décès en relation avec l’abus de médicaments et substances (DRAMES) et nouveaux produits de synthèse (NPS) : combien de cas depuis 5 ans ? Toxicologie Analytique et Clinique 2018. [DOI: 10.1016/j.toxac.2018.04.064] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
7
|
Eysseric H, Allibe N, Fouilhé Sam-Laï N, Bartoli M, Bruyère R, Protar D, Cuisinier A, Nemoz B, Mallaret M, Scolan V, Stanke-Labesque F. Norcarfentanil, un métabolite d’intérêt dans le diagnostic toxicologique : à propos de 3 hospitalisations. Toxicologie Analytique et Clinique 2018. [DOI: 10.1016/j.toxac.2018.04.059] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
8
|
Yahiaoui N, Roche M, Aissaoui-Hoffmann N, Keita BA, Mallaret M. Intravenous methylprednisolone induced acute pancreatitis. Eur J Clin Pharmacol 2017; 73:645-646. [DOI: 10.1007/s00228-017-2207-5] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/29/2016] [Accepted: 01/19/2017] [Indexed: 10/20/2022]
|
9
|
Jonville-Bera AP, Vial T, Sgro C, Mallaret M. Vaccins contre les rotavirus : quelques précisions sur les circonstances du non remboursement (en réponse à l’article « Info vaccins » de Cohen R. et al.). Arch Pediatr 2016; 23:655-7. [DOI: 10.1016/j.arcped.2016.02.005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/11/2016] [Revised: 01/21/2016] [Accepted: 02/10/2016] [Indexed: 11/17/2022]
|
10
|
Carré G, Mallaret M, Lagha-Boukbiza O, Dietemann J, Namer I, Anheim M, Tranchant C. Malformation d’Arnold Chiari secondaire à une hyperostose de la voûte crânienne révélée par une ataxie cérébelleuse. Rev Neurol (Paris) 2015. [DOI: 10.1016/j.neurol.2015.01.253] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
11
|
Marelli C, Salih MM, Nguyen K, Mallaret M, Drouot N, Labauge P, Koenig M. Paraparésie spastique héréditaire à phénotype complexe avec mutation dans le gène FA2H : description de 5 cas. Rev Neurol (Paris) 2014. [DOI: 10.1016/j.neurol.2014.01.405] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
12
|
Montaut S, Mallaret M, Lagha-Boukbiza O, Echaniz-Laguna A, Entz Werlé N, Anheim M, Tranchant C. Une encéphalopathie avec anticorps anti-HU associée à un ganglioneuroblastome chez une jeune adulte. Rev Neurol (Paris) 2014. [DOI: 10.1016/j.neurol.2014.01.199] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
13
|
Renaud M, Mallaret M, Drouot N, Mandel JL, Anheim M, Tranchant C, Koenig M. Capture ciblée d’exons de gènes d’ataxie couplée au séquençage à haut débit. Rev Neurol (Paris) 2013. [DOI: 10.1016/j.neurol.2013.01.039] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
14
|
Smyth T, Sheehan M, Siskind V, Mercier-Guyon C, Mallaret M. Consumer perceptions of medication warnings about driving: a comparison of French and Australian labels. Traffic Inj Prev 2013; 14:557-564. [PMID: 23859486 DOI: 10.1080/15389588.2012.729278] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/02/2023]
Abstract
OBJECTIVE Little research has examined user perceptions of medication warnings about driving. Consumer perceptions of the Australian national approach to medication warnings about driving are examined. The Australian approach to warning presentation is compared with an alternative approach used in France. Visual characteristics of the warnings and overall warning readability are investigated. Risk perceptions and behavioral intentions associated with the warnings are also examined. METHOD Surveys were conducted with 358 public hospital outpatients in Queensland, Australia. Extending this investigation is a supplementary comparison study of French hospital outpatients (n = 75). RESULTS The results suggest that the Australian warning approach of using a combination of visual characteristics is important for consumers but that the use of a pictogram could enhance effects. Significantly higher levels of risk perception were found among the sample for the French highest severity label compared to the analogous mandatory Australian warning, with a similar trend evident in the French study results. The results also indicated that the French label was associated with more cautious behavioral intentions. CONCLUSION The results are potentially important for the Australian approach to medication warnings about driving impairment. The research contributes practical findings that can be used to enhance the effectiveness of warnings and develop countermeasures in this area. Hospital pharmacy patients should include persons with the highest level of likelihood of knowledge and awareness of medication warning labeling. Even in this context it appears that a review of the Australian warning system would be useful particularly in the context of increasing evidence relating to associated driving risks. Reviewing text size and readability of messages including the addition of pictograms, as well as clarifying the importance of potential risk in a general community context, is recommended for consideration and further research.
Collapse
Affiliation(s)
- T Smyth
- Centre for Accident Research and Road Safety-Queensland, Queensland University of Technology, Queensland, Australia.
| | | | | | | | | |
Collapse
|
15
|
Marcel C, Mallaret M, Lagha-Boukbiza O, Kremer S, Echaniz-Laguna A, Tranchant C. L-2-hydroxyglutaric aciduria diagnosed in a young adult with progressive cerebellar ataxia and facial dyskinesia. Rev Neurol (Paris) 2012; 168:187-91. [DOI: 10.1016/j.neurol.2011.06.002] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/03/2011] [Revised: 06/03/2011] [Accepted: 06/17/2011] [Indexed: 01/27/2023]
|
16
|
Gibert P, Logerot S, Bourneau D, Desbois A, Amiard S, Mallaret M, Calop J, Gavazzi G. Calcium-heparinate induced skin necrosis without thrombocytopenia. Eur Geriatr Med 2011. [DOI: 10.1016/j.eurger.2011.06.005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
17
|
Gibert P, Mazière S, Trinh I, Mallaret M, Allenet B, Calop J, Gavazzi G. Révélation tardive de la potentialisation de l’activité anticoagulante des antivitamines K par le miconazole bioadhésif (LORAMYC®) : à propos de trois cas. Rev Med Interne 2010. [DOI: 10.1016/j.revmed.2010.10.273] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
18
|
Abstract
In response to the increase of resistant depressive disorders and in spite of improved treatments, numerous studies were conducted in the last thirty Years aiming at assessing the pre-morbid thyroid state of depressed patients resistant to well conducted tricyclic treatments. "Minimal" thyroid abnormalities were evidenced as well as central thyroid disorders which may not be detected by peripheral-i.e plasmatic- dosages. Regarding the premorbid thyroid status, the hypothesis of subclinical hypothyroidism was considered by many Authors. It is marked by four grades including T3 and T4 decreased levels, basal TSH concentration abnormalities as well as increased TSH response to TRH stimulation, and the presence of antimicrosomal and antithyroglobulin antibodies. Although, there are different views on the existence or not of these abnormalities, we'll focus our attention on a metaanalysis including six studies. It shows in a population with a resistant depression, 52% of patients with subclinical hypothyroidism, against 8 to 17% in patients with simple depression and 5% in the overall population.Similarly, antithyroid antibody levels (group IV hypothyroidism) were significantly higher in depressed patients (9% to 20% against 7,5% in the overall population). For many Years, a central hypothyroidism was hypothesized on the basis of an exhausted T3-T4 transference mechanism and a lowered TRH hypothalamic biodisponibility.In the last Years, new data emerged on the role of transthyretin, a cerebral carrier T4 protein, whose concentration in the CSF was found significantly lower in depressed patients than in a control group, the lowest levels being observed in the most severely depressed. This decreased level of transthyretin would result in a lower central T4 biodisponibility-hence, in view of a T4-T3 desiodation insufficiency, a T3 deficit is observed. A low transthyretin level associated or not to subclinical hypothyroidism could be a factor of depressive vulnerability on one hand, of resistance to tricyclic treatment on the other one. Conversely, subclinical hypothyroidism could be a predictive factor of a good response to a potentializing strategy. The pharmacological mechanisms involved in this potentializing phenomenon are now well known: they consist in an interaction between depression, adrenergic receptors and thyroid hormones biodisponibility. The decreased norepinephrine level observed in depressive patients is associated, in case of increased thyroid hormones biodisponibility, with a higher sensitivity of adre-nergic receptors, mostly betaadrenergic. This seems to underly the recovery process. According to some Authors, the serotoninergic system might be involved in the potentialization of tricyclics by thyroid hormones. We know that in animals with hypothyroidism, the serotonin synthesis is decreased and that the administration of T3 increases the brain levels of serotonin and its 5HIA catabolite. In addition, T3 could correct the down-regulation induced by serotoninergics on beta-adrenergic receptors. On the basis of numerous studies carried out on the potentializing of tricyclics, we suggest practical modalities of treatment - which until today did not materialize in every day practice in the absence of a clear consensus based on statistically reliable data: after four to six weeks of inefficient tricyclic or serotoninergic treatment on a correct dosage testified by plasmatic dosages, it is recommended to initiate a T3 treatment on a effective posology (25 to 50 micrograms per day), which must be reached in 2 or 3 days, except in case of rare and transitory side effects (sweating, shaking, tachycardia, nervousness, anxiety). If the treatment is not rapidly efficient, it must be discontinued in case there is no improvement after 3 weeks. Until today, there is no consensus about the duration of a T3 treatment. It is important to take into account the predictive criteria of good or bad response to a T3 potentialization, since they have direct consequences on the management of depressed patients. For example, a high degree of chronic evolution with resistance to numerous treatments, associated disorders according to the DSM IV axis I and a comorbidity of addiction, point to a bad prognosis of a potentialization treatment. In addition, we'll examine the few recent studies on the potentializing of serotoninergic antidepressant drugs by thyroid hormones.
Collapse
Affiliation(s)
- F Sintzel
- Service de Psychiatrie de l'Adulte, Hôpitaux du Léman, 74203 Thonon
| | | | | |
Collapse
|
19
|
Mara C, Sarrot-Reynauld F, Mallaret M, Raclot-Roy N, Massot C. Toxidermie à l'ivermectine au cours du traitement d'une gale profuse hyperkératosique. Rev Med Interne 2004; 25:476-7. [PMID: 15158324 DOI: 10.1016/j.revmed.2004.02.021] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/12/2003] [Accepted: 02/15/2004] [Indexed: 11/23/2022]
|
20
|
Chen C, Chevrot D, Contamin C, Romanet T, Allenet B, Mallaret M. [Stomatitis and ageusia induced by candesartan]. Nephrologie 2004; 25:97-9. [PMID: 15185557] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 04/29/2023]
Abstract
Cases of dysgeusia or ageusia have been reported in patients treated with angiotensin II receptor antagonist such as losartan (5 cases), valsartan (1 case), eprosartan (1 case). This is the first case-report of ageusia following candesartan. A 46-year-old-male patient, with a medical history of renal chronic reject allograft disease, started candesartan 4 mg once daily to treat high blood pressure. Six months later, a progressive ageusia occurred with a burning mouth syndrome. He also developed aphthous ulcers of the mouth, stomatitis and perleche, which led him to lose 8 kilos within 13 months. Thirteen months after the beginning of the treatment candesartan was stopped. The symptoms and lesions required 2 to 3 weeks to disappear. Subsequently, appetite was found again as well as the sense of taste. The temporal sequence of events suggests a causal relationship between ageusia and candesartan.
Collapse
Affiliation(s)
- C Chen
- Département pharmacie, CHU de Grenoble.
| | | | | | | | | | | |
Collapse
|
21
|
Sarrot-Reynauld F, Mara C, Mallaret M, Raclot-Roy N, Massot C. Toxidermie à l'ivermectine au cours du traitementd'une gale norvégienne. Rev Med Interne 2003. [DOI: 10.1016/s0248-8663(03)80629-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
22
|
Lagrue G, Le Foll B, Melihan-Cheinin P, Rostoker G, Ades J, de Beaurepaire R, Berlin Y, Borgne A, Coninx P, Dautzenberg B, Dally S, Divine C, Denis C, Dumarcet N, Dupont P, Jeanjean A, Lagier G, Lebargy F, Leder JM, Legeron P, Le Pen C, Mallaret M, Menard J, Messina C, Molimard R, Mussetta B, Peiffer G, Pons F, Robine I, Saint-Salvi B, Stoebner A, Bouvenot G, Bergmann JF, Caulin C, Dupuis B, Aubier M, Bannwarth B, Camelli B, Castot A, Funk-Brentano C, Le Jeunne C, Meyer F, Petit M, Reveillaud O, Riche C, Rostoker G, Thery C, Tremolieres F, Trouvin JH, Wong O. [Clinical practice guideline: medical and nonmedical therapeutic strategies for smoking cessation. Bit of therapeutic practice: management and current practice in smoking cessation]. Rev Mal Respir 2003; 20:791-4. [PMID: 14631264] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/27/2023]
|
23
|
Saviuc P, Dematteis M, Mezin P, Danel V, Mallaret M. Toxicity of the Clitocybe amoenolens mushroom in the rat. Vet Hum Toxicol 2003; 45:180-2. [PMID: 12882485] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 03/03/2023]
Abstract
Ingestion of Clitocybe amoenolens, a mushroom collected in Savoie (France), induced erythermalgia in 5 patients. To assess C. amoenolens toxicity, increasing doses were given randomly to 4 rats corresponding to 1 to 25 fold the dose eaten by the most severely poisoned patient. The 2 rats receiving the highest doses had loss of bodyweight, locomotor disability and erythema of the toes. Examination of sciatic nerves showed decreased axon density and neuronal fiber degeneration. Oral administration of C. amoenolens to rats led to lesions that might be explained by the presence of acromelic acid A, a kainate analogue.
Collapse
Affiliation(s)
- P Saviuc
- Unité de Toxicologie Clinique, Centre Régional de Pharmacovigilance, CHU, BP217, 38043 Grenoble cedex 9, France
| | | | | | | | | |
Collapse
|
24
|
Abstract
PURPOSE The new opioids and the new galenic forms, now available in France, require an update in practitioners' knowledge. The purpose of the present study is to help those prescribing select the appropriate opioid and its galenic form for pain relief. CURRENT KNOWLEDGE AND KEY POINTS Presentation of pharmacological properties of opioids (mechanisms, pharmacokinetics and pharmacovigilance). Presentation of indications, modes of prescription and use of main opioids for pain (especially cancer pain). Examples for calculating required drug dosage depending on the clinical situation and the route of administration. Symptomatic treatments of the main undesirable side effects of the opioids, and actions to be taken in the event of accidental overdose. FUTURE PROSPECTS AND PROJECTS Oral morphine is the treatment first recommended for nociceptive pain insufficiently relieved by WHO level I and II analgesics. The new immediate-release galenic forms allow morphine titration and the treatment of breakthrough pain. Transmucosal fentanyl, soon available in France, is recommended for breakthrough pain in patients already under opioid treatment: it gives more rapid relied starting after only 5 minutes and it only acts for a short time. Transdermal fentanyl is indicated for stable cancer pain. It is particularly suitable when oral and injectable morphine routes are not available, or for patients with severe constipation. Hydromorphone is the first opioid recommended in France for severe cancer pain when morphine resistance exists or uncontrolled side effects are present (opioid rotation). The new opioids and the new galenic forms widen the range of therapeutic possibilities. Their use is well codified for cancer pain and must still undergo clinical trials for chronic non-cancer pain. When correctly indicated, opioid selection provides a considerable advance in pain management.
Collapse
Affiliation(s)
- G Laval
- Unité de recherche et de soutien en soins palliatifs, CHU, BP 217, 38043 Grenoble, France.
| | | | | | | |
Collapse
|
25
|
Chritin M, Besson G, Mallaret M, Savasta M. [Amyotrophic lateral sclerosis and animal models]. Rev Neurol (Paris) 2001; 157:1351-61. [PMID: 11924004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/24/2023]
Abstract
Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease which affects cortical, bulbar and spinal motoneurones. The cause of the disease, probably due to several factors, is still unknown and the survival delay of patients with ALS generally does not exceed 3-5 years. Animals models provide a unique opportunity to study pathological features and to evaluate potential therapeutic effects of news treatments. Natural disease models, neurotoxins or viral-induced models and more recently transgenic models with genetic anomalies mimicking those found in ALS patients have been extensively studied. This review summarizes the most relevant clinical and pathological advances issuing from these animal studies.
Collapse
Affiliation(s)
- M Chritin
- Service de Neurologie, CHU de Grenoble
| | | | | | | |
Collapse
|
26
|
Abstract
Abstract MBDB (N -methyl-1-(1,3-benzodioxol-5-yl)-2-aminobutane) is the alpha-ethyl homologue of MDMA (3,4-methylenedioxy-N-methylamphetamine). MBDB is metabolized and excreted similarly to MDMA: presumably, the majority of oral MBDB is excreted in urine unmetabolized.The main metabolic routes in man are thought to be O-dealkylation and subsequent methylation, sulphation and glucuronidation of the newly formed hydroxy groups. The major acute neuropharmacological effects of MBDB in the rat are an increase in serotonin release in the brain and an inhibition of serotonin and noradrenaline re-uptake. These effects compare well with those of MDMA, although the latter is more potent. MBDB may also slightly increase dopamine release and inhibit dopamine re-uptake, but to a lesser extent than MDMA. This is important, as dopamine release has been implicated in the reinforcing qualities of substances such as cocaine and amphetamine. The neuroendocrine effects of MBDB resemble those of MDMA. Both substances increase plasma ACTH, corticosterone, prolactin and renin. The neurophysiological effects of MBDB are characterized by a decrease in electrical activity throughout the brain, most notably in the alpha 2 and delta frequency bands. In contrast, hallucinogens increase the activity in the alpha 1 band, especially in the corpus striatum. In drug discrimination tests in the rat, MBDB, like MDMA, can be distinguished clearly from both stimulants and hallucinogens.The class of substances to which MBDB belongs may be named entactogens. MBDB dose-dependently increases locomotor activity and decreases exploratory behaviour in the rat and causes distress vocalization and wing extension in the newly hatched chicken. The rewarding properties of MBDB appear to be smaller than those of MDMA, as suggested by a 2.5 times weaker potency in the conditioned place preference test in rats. The main subjective effects of MBDB in man are a pleasant state of introspection, with greatly facilitated interpersonal communication and a pronounced sense of empathy and compassion between subjects. In this respect, MBDB again resembles MDMA. However, there are also differences. MBDB has a slower and more gentle onset of action than MDMA, produces less euphoria and has less stimulant properties. The few toxicological data available suggest that MBDB may cause serotonergic deficits in the brain, although the potency of MBDB to cause this neurotoxic effect is smaller than that of MDMA. Severe acute reactions in man as have been reported for MDMA have not been published for MBDB. The dependence potential of MBDB appears to be small, probably even smaller than that of MDMA. MBDB has been available at least since 1994 but its position on the synthetic drugs market is marginal. Subjective reports indicate that MBDB is less popular among users than MDMA. The reason may be that MBDB produces less euphoria than MDMA. Another possible explanation is that MBDB largely lacks the stimulant properties of MDMA.We calculated a margin of safety with a method similar to one used in the risk assessment of pharmaceuticals. The results suggest that MBDB is three times less likely to cause serotonergic brain deficits than MDMA. However, it should be noted that for both substances the margin of safety is less than one, indicating that the risk of neurotoxicity is not negligible. In animals, serotonergic brain deficits after exposure to MDMA have been linked to the degeneration of serotonergic nerve terminals.
Collapse
Affiliation(s)
- L A Aerts
- Trimbos Institute, Netherlands Institute of Mental Health and Addiction, Utrecht, The Netherlands
| | | | | |
Collapse
|
27
|
Hardy G, Saviuc P, Danel V, Lafond JL, Mallaret M. [Bromide poisoning and false hyperchloremia]. Ann Fr Anesth Reanim 2000; 19:363-6. [PMID: 10874435] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/16/2023]
Abstract
A 36-year-old female patient was admitted at three different times for neuropsychiatric disorders. No diagnoses were made during the first two hospital stays. A pseudohyperchloraemia allowed the diagnosis of bromide poisoning during her third hospital stay. Chloraemia was measured over 16 days by potentiometric, colorimetric and coulometric methods, in order to assess the analytical interferences caused by bromides. Results are reported and discussed. Bromide poisoning was treated by saline diuresis.
Collapse
Affiliation(s)
- G Hardy
- Laboratoire de pharmacologie et toxicologie, centre hospitalier, Grenoble, France
| | | | | | | | | |
Collapse
|
28
|
Vincent F, Bessard J, Vacheron J, Mallaret M, Bessard G. Determination of buprenorphine and norbuprenorphine in urine and hair by gas chromatography-mass spectrometry. J Anal Toxicol 1999; 23:270-9. [PMID: 10445490 DOI: 10.1093/jat/23.4.270] [Citation(s) in RCA: 35] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
Buprenorphine, which is used in France as a substitution drug for opioid addiction, is widely abused, and several fatal cases have been reported. In order to confirm a recent intoxication or to establish retrospectively chronic abuse, a simple and reliable gas chromatographic-mass spectrometric method was developed and validated for quantitation of buprenorphine and its active metabolite norbuprenorphine in urine and hair. Two milliliters of urine or 50 mg of pulverized hair was submitted to a pretreatment (enzymatic hydrolysis for urine and decontamination with dichloromethane followed by incubation in 0.1 M HCI for hair). Buprenorphine-d4 was chosen as the internal standard. Selective solid-phase extraction with Bond Elut Certify columns provided recoveries higher than 85% for urine and 43% for hair. By using a mixture of MSTFA/TMSIM/TMCS (100:2:5), buprenorphine and norbuprenorphine produced stable silylated derivatives. The detection was carried out with a quadrupole mass detector working in El selected ion monitoring mode. Ions at m/z 450 and 468 were chosen for the quantitation of buprenorphine and norbuprenorphine, respectively (m/z 454 was used for the internal standard). Limits of quantitation were 0.25 and 0.20 ng/mL, respectively, for buprenorphine and norbuprenorphine in urine and 0.005 ng/mg for the two compounds in hair. Calibration curves were linear from 0 to 50 ng/mL in urine and from 0 to 0.4 ng/mg in hair. Between-day and within-day precisions were less than 8.4% in hair and 6.1% in urine for both molecules in all cases. This method was applied to urine and hair samples collected from patients in a withdrawal treatment program and demonstrated its good applicability in routine analysis and its benefit for clinicians. This technique, which requires instruments already available to many toxicology laboratories, offers an attractive alternative to more sophisticated techniques.
Collapse
Affiliation(s)
- F Vincent
- Laboratoire de Pharmacologie et Analyses Toxicologiques, Centre Hospitalier Universitaire de Grenoble, France
| | | | | | | | | |
Collapse
|
29
|
|
30
|
Piquet C, Mallaret M, Bontemps H, Fabre M, Sarrot-Reynaud F, Imbert B. [Adverse effects and medication errors: incidence and role of the organization of drug distribution]. Therapie 1999; 54:49-53. [PMID: 10216422] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/12/2023]
Abstract
The true incidence of adverse drug events is controversial and there are few data concerning the percentage of potentially preventable adverse drug events. Over 2 months, in two internal medicine units, we asked the staff to report adverse drug events. All incidents were evaluated: adverse drug events (preventable and non-preventable) and potential adverse drug events (non-intercepted potential adverse drug events and intercepted potential adverse drug events). The severity, the stage in the process at which the error occurred and the type of error were evaluated by a physician reviewer. Over the 240 admissions, the incidence of adverse drug events is 18 per 1000 patient-days. The system design caused 77 per cent of the incidents. The medication errors occurred at all stages from ordering to administration. Adverse drug events resulting in medication errors (n = 22) were more serious than non-preventable adverse drug events (n = 26) (p = 0.003). A prevention strategy by pharmacovigilance centres (Centres Régionaux de Pharmacovigilance) should target all stages of the drug delivery process.
Collapse
Affiliation(s)
- C Piquet
- Service de Médicine Interne et Toxicologie, CHU Grenoble
| | | | | | | | | | | |
Collapse
|
31
|
Abstract
Dextromethorphan (DM), a widely used and well-tolerated centrally acting antitussive, has been tested in several clinical trials for its antiepileptic and neuroprotective properties. However, the use of DM in these new clinical indications requires higher doses than antitussive doses, which may therefore induce phencyclidine (PCP)-like side-effects (memory and psychotomimetic disturbances) through its metabolic conversion to the active metabolite dextrorphan (DX), a more potent PCP-like non-competitive antagonist at the N-methyl-D-aspartate (NMDA) receptor than DM. Thus, we compared the behavioural effects in rats of intraperitoneal administration of DM and DX on motor activity in an open field and on learning and memory in the Morris water maze. DM (20, 30, 40 mg/kg) produced a dose-dependent decrease in both locomotion and stereotyped behaviour with a slight ataxia for the highest dose. DX (20, 30, 40 mg/kg) induced a dose-dependent increase in locomotion and stereotypies (swaying, turning) with moderate ataxia. Assessments of learning and memory were performed with lower doses of DM (10, 20, 30 mg/kg) and DX (5, 10, 15 mg/kg) because of motivational deficits (40 mg/kg of DM, 20-40 mg/kg of DX) and motor disorders (30, 40 mg/kg of DX) in the cue learning procedure. DX (10, 15 mg/kg) impaired spatial learning with a long-lasting effect for the highest dose whereas 5 mg/kg of DX and DM (10-30 mg/kg) did not. Only 15 mg/kg of DX appeared to slightly impair working memory. DM (10-30 mg/kg) and DX (5-15 mg/kg) did not impair reference memory. Thus, the two antitussives DM and DX induced different behavioural effects suggesting sedative effects for DM and PCP-like effects for DX. However, PCP-like side-effects with DM remain possible through its metabolic conversion to DX, with very high doses and/or in extensive metabolizers and/or in aged subjects prone to cognitive dysfunction. Therefore, the identification of DM metabolism phenotype, an adapted prescription and a pharmacological modulation of the DM metabolism may avoid adverse effects.
Collapse
Affiliation(s)
- M Dematteis
- Unité de Neuropharmacologie, CRSSA, La Tronche, France
| | | | | |
Collapse
|
32
|
Dematteis M, Mallaret M, Baubichon D, Pernot-Marino I, Lallement G. Evaluation of dextromethorphan and dextrorphan as a preventive treatment of soman toxicity in mice. Neurosci Lett 1997; 234:91-4. [PMID: 9364505 DOI: 10.1016/s0304-3940(97)00682-4] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
Phencyclidine-like drugs are effective against convulsions and brain lesions related to soman intoxication but induce severe side effects. The well tolerated antitussive dextromethorphan (DM) and its metabolite dextrorphan (DX) have antiepileptic and neuroprotective properties that we evaluated in mice against 2 LD50 of soman in a three-drug pretreatment (atropine sulfate and oxime HI-6 plus DM: 20-50 mg/kg or DX: 10-40 mg/kg i.p). Neuroprotection was evaluated by measurement of hippocampal omega 3 binding site density. DM and DX have weak anticonvulsant and neuroprotective activities which are counterbalanced at high doses by an increased mortality due to respiratory distress for DM and by ataxia for DX. Thus DM and DX do not appear to be appropriate for the pretreatment of soman intoxication.
Collapse
Affiliation(s)
- M Dematteis
- Department of Neurology, University Hospital of Grenoble, France
| | | | | | | | | |
Collapse
|
33
|
Lauby V, Mallaret M, Dufrêne I, Amalfitano G, Stanke F. [Macrolides and drug interactions: review of the literature]. Therapie 1996; 51:177-84. [PMID: 8763053] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
Clarithromycin, azithromycin and dirithromycin have recently been introduced in France. We list the different drug-interactions with these three new drugs and with erythromycin, josamycin, roxithromycin, midecamycin and spiramycin.
Collapse
Affiliation(s)
- V Lauby
- Centre Régional de Pharmacovigilance, Grenoble, France
| | | | | | | | | |
Collapse
|
34
|
Amalfitano G, Pernod G, Mallaret M, Barjhoux C, Berger F, Besson G, Pasquier B. [Risk of intracerebral hematoma and profibrinolytic activity of isotretinoin]. Therapie 1995; 50:479-81. [PMID: 8571296] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/31/2023]
|
35
|
Juge S, Lauby V, Mallaret M, Musiedlak G, Stanke F, Bessard G. [Interactions between ergot derivatives and macrolides are still topical: ravages of self medication]. Rev Med Interne 1995; 16:295. [PMID: 7746974 DOI: 10.1016/0248-8663(96)80714-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
|
36
|
Abstract
We report the two first cases of neuropsychic side-effects with zipeprol (non opiate antitussive) given at therapeutic doses. In both cases, the patients showed confusion, whereas, hallucinations occurred only in one case. The anticholinergic activity of zipeprol might explain these effects. These two cases are in agreement with zipeprol central nervous system action.
Collapse
Affiliation(s)
- V Lauby
- Centre régional de pharmacovigilance, CHU de Grenoble, France
| | | | | | | | | |
Collapse
|
37
|
Abstract
Male Sprague-Dawley rats were trained to discriminate dextromethorphan (DM, 30 mg/kg, ip) from saline using a standard two-lever, fixed ratio 10, food reinforcement procedure. The DM-saline discrimination was acquired, and a range of doses of DM produced a dose-related generalization to the DM-lever choice. Stimulus generalization tests were conducted with dextrorphan, an active metabolite of DM, and with drugs selected from different pharmacological families. Dextrorphan induced a full generalization to DM, but only at a dose higher than the DM training dose. Morphine, a mu opiate receptors agonist, and U 50488, a kappa opiate receptors agonist, failed to substitute for DM. Cyclazocine, a benzomorphan derivative, with high affinity for sigma receptors, was able to produce a complete generalization to DM, without a change in the number of rats responding. Dizocilpine (MK 801), a phencyclidine-like drug, produced a complete generalization, but only at a dose that markedly reduced the number of rats responding. Carbetapentane and caramiphen, antitussive drugs with high affinity for the 'specific DM receptors', failed to substitute for DM. These results show that the discriminative stimulus of DM, did not result primarily from its metabolism to dextrorphan; and the discriminative stimulus properties of DM appear to more closely resemble those of cyclazocine than those of the other drugs tested. This suggests a role of sigma receptors in the mediation of the DM stimulus. These experimental data are discussed with reference to the cyclazocine-like subjective effects produced in man by large doses of DM.
Collapse
Affiliation(s)
- M Gavend
- Laboratoire de Pharmacologie, Faculté de Médecine de Grenoble, France
| | | | | | | |
Collapse
|
38
|
|
39
|
Moulin CH, Rolachon A, Cohard M, Girard M, Bichard P, Pasquier D, Mallaret M, Zarski JP. [Fulminant hepatitis secondary to alprazolam]. Therapie 1994; 49:362-3. [PMID: 7878609] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
|
40
|
Lauby V, Mallaret M, Rivière I, Barthe I, Coquilhat P. [Precipitation of opioid withdrawal syndrome with nalbuphine in a morphine dependent cancer patient]. Therapie 1994; 49:143-4. [PMID: 7817340] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
|
41
|
Rivière I, Barjhoux C, Mallaret M. [Hemoptysis under acenocoumarol: role of the arrest of enzymatic inductor (carbamazepine)]. Therapie 1994; 49:142-3. [PMID: 7817339] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
|
42
|
|
43
|
Abstract
BACKGROUND Cerebral venous sinus thrombosis is rare and can be promoted by various conditions. We report the case of cerebral venous thrombosis in a patient using androgens. CASE DESCRIPTION A 31-year-old man using androgens for bodybuilding was admitted for headache and vomiting. He had cerebral venous sinus thrombosis, but extensive examinations did not reveal any known cause. CONCLUSIONS We suggest that androgens may promote cerebral venous thrombosis. The mechanisms of venous thrombosis related to androgens may be platelet activation or an increase in coagulation factors. Because androgen use may be frequent and hidden in athletes, it may be an underestimated cause of cerebral venous sinus thrombosis in the young.
Collapse
Affiliation(s)
- A S Jaillard
- Département de Neurosciences Cliniques et Biologiques, Centre Hospitalier Universitaire de Grenoble, France
| | | | | |
Collapse
|
44
|
Mallaret M, Mezin P, Chartier A. [Rhabdomyolysis in hypothyroidism. Favourable role of amiodarone]. Presse Med 1993; 22:272. [PMID: 8511151] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/31/2023] Open
|
45
|
Gavend M, Mallaret M, Caron F, Baragatti G. Antagonism of metergoline on the diuretic effect of cyclazocine and U-50488 drugs with a kappa agonist activity. Biomed Pharmacother 1993; 47:337-44. [PMID: 8061255 DOI: 10.1016/0753-3322(93)90083-w] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023] Open
Abstract
In rats receiving a normal saline load of 2.5 ml/100 g, sc, (moderately hydrated rats), injections of the serotonin (5-HT) antagonist, metergoline (0.25-1-4 mg/kg), resulted in a dose-dependent decrease in the urine output induced by a dose of 8 mg/kg of cyclazocine (a benzomorphan derivative, mixed kappa and sigma agonist) at the 2-h time period. The antagonist effect of metergoline (1 mg/kg) on cyclazocine doses ranging from 0.25 to 8 mg/kg, was observed only at 2 mg/kg higher doses. Other 5-HT receptor blockers, methysergide, pizotifen, cyproheptadine, caused a significant degree of antagonism. In rats receiving a saline load and a water load of 5.5 ml/100 g, ip (hyperhydrated rats), metergoline (1 mg/kg) completely antagonized the diuretic effect of cyclazocine (8 mg/kg) at the 4-h and 5-h time periods. Similarly, metergoline (1 and 4 mg/kg) administered in moderately hydrated rats, markedly decreased at the 2-h time period, the urine output produced by 5 mg/kg of U-50488 (a non benzomorphan derivative, highly selective kappa agonist), and in hyperhydrated rats, completely suppressed, at the 4-h and 5-h time periods the drug-induced diuresis. Metergoline administered alone had no effect on urine output in moderately hydrated rats or in hyperhydrated rats. These results suggest the hypothesis that 5-HT may be involved in the complex mechanisms of kappa agonist-induced diuresis in rats.
Collapse
Affiliation(s)
- M Gavend
- Laboratoire de Pharmacologie, Faculté de Médecine de Grenoble, La Tronche, France
| | | | | | | |
Collapse
|
46
|
Perron H, Gratacap B, Lalande B, Genoulaz O, Laurent A, Geny C, Mallaret M, Innocenti P, Schuller E, Stoebner P. In vitro transmission and antigenicity of a retrovirus isolated from a multiple sclerosis patient. Res Virol 1992; 143:337-50. [PMID: 1282730 DOI: 10.1016/s0923-2516(06)80122-6] [Citation(s) in RCA: 30] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
Abstract
We have recently isolated an apparently novel retrovirus (LM7) from a patient with multiple sclerosis (MS). We present here results showing that (1) LM7 retrovirus can be transmitted in vitro to a normal human leptomeningeal cell culture and that (2) specific antibody against this retroviral strain can be detected in MS cases. Our results suggest that, if this virus is an endogenous retrovirus, it is different from human endogenous elements already described.
Collapse
Affiliation(s)
- H Perron
- UMR 103 CNRS/BioMérieux, Ecole Normale Supérieure de Lyon, France
| | | | | | | | | | | | | | | | | | | |
Collapse
|
47
|
Perron H, Lalande B, Gratacap B, Laurent A, Genoulaz O, Geny C, Mallaret M, Schuller E, Stoebner P, Seigneurin JM. Isolation of retrovirus from patients with multiple sclerosis. Lancet 1991; 337:862-3. [PMID: 1707471 DOI: 10.1016/0140-6736(91)92579-q] [Citation(s) in RCA: 98] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
|
48
|
Vial T, Laine V, Delcombel M, Goubier C, Galland MC, Mallaret M, Descotes J. [Vasculitis after anti-influenza vaccination. Report of 5 cases]. Therapie 1990; 45:509-12. [PMID: 2080490] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Abstract
We describe five cases of vasculitis noted a few days after influenza vaccination. This complication has occurred in four women, and the mean age was 76 years. Although cutaneous biopsy has confirmed leucocytoclasic vasculitis in only one case, the clinical characteristics were evocative in the other cases. No systemic complication were noted. Spontaneous retrocession was noted in four patients and following corticosteroids once. To our knowledge only few cases of vasculitis has been previously reported after influenza vaccination. The mechanisms are unknown but preservatives may have some responsibilities.
Collapse
Affiliation(s)
- T Vial
- Centre de Pharmaco-Toxicovigilance, Hôpital E. Herriot, Lyon
| | | | | | | | | | | | | |
Collapse
|
49
|
Hardelin D, Saviuc P, Mallaret M, Brousse P, Danel V. [Eosinophilic myalgia from L-tryptophan]. J Toxicol Clin Exp 1990; 10:409-12. [PMID: 2130184] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
|
50
|
Orfeuvre H, Brion JP, Mallaret M, Aubert D, Micoud M. [Occurrence of methemoglobinemia induced by dapsone in the treatment of pneumocystosis associated with AIDS]. Therapie 1989; 44:451-2. [PMID: 2623659] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
|